Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Insulet

Neurocrine Leads 5 Stocks To Watch In Sickly Market

Neurocrine Biosciences leads five medical stocks near key support levels as the health care sector shows resilience in a sickly market.

Investors Business Daily

Dow Jones Futures: Market Expects This From Fed Chief Powell; 5 Stocks In Buy Zones

Several stocks flashed buy signals as the market rallied heading into Fed chief Powell's speech. Here's what to expect.

Investors Business Daily

Recap Of Monday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has announced clearance to Insulet’s (NASDAQ:PODD) Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for individuals aged two years and older with type 1 diabetes (T1D). Insulet shares traded in a range of $260.13 to $266.73 on day volume of 200.86 thousand shares…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Dow Jones Futures Fall As Market Retreat Gains Steam; Elon Musk Makes This FSD Move

Futures fell sharply as the market rally pulls back. Elon Musk will hike Tesla FSD prices. Warren Buffett stock Occidental Petroleum surged Friday.

Investors Business Daily

IBD Stock Of The Day Insulet Edges Closer To A Breakout On This 'Game Changer'

Insulet is the IBD Stock Of The Day as excitement around the company's new insulin pump, Omnipod 5, drives PODD stock closer to a breakout.

Investors Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For July 11, 2022

Upgrades

Benzinga

5 Analysts Have This to Say About Insulet

Insulet (NASDAQ:PODD) has observed the following analyst ratings within the last quarter:

Benzinga

Read news from The Economist, FT, and more,
with one subscription

4 Analysts Have This to Say About Insulet

Analysts have provided the following ratings for Insulet (NASDAQ:PODD) within the last quarter:

Benzinga

Dexcom Pops After Insulet Buyout Rumor Shakes Up Diabetes Stocks

Dexcom stock popped Tuesday after the diabetes devices company refuted rumors that it's in active negotiations to acquire any company.

Investors Business Daily

Looking Into Insulet's Return On Capital Employed

According to Benzinga Pro, during Q1, Insulet (NASDAQ:PODD) earned $27.80 million, a 4.79% increase from the preceding quarter. Insulet's sales decreased to $295.40 million, a 4.0% change since Q4.

Benzinga

How The Rumored Dexcom-Insulet Marriage Could Rock The Entire Diabetes Space

Dexcom stock yo-yoed Wednesday after a Tuesday dive on rumors it's in talks to acquire insulin pump-maker Insulet in a major diabetes deal.

Investors Business Daily

Dexcom In Talks To Acquire Insulet, Create a Giant In Diabetes Devices: Bloomberg

Dexcom Inc (NYSE:DXCM) is reportedly in talks to acquire medical-device company Insulet Corporation (NASDAQ: PODD) to create a giant in diabetes devices, according to people with knowledge of the matter. According to Bloomberg, talks between the companies are ongoing, and an agreement could be reached in the coming weeks. Discussions could still be delayed or fall…

Benzinga

Expert Ratings for Insulet

Within the last quarter, Insulet (NASDAQ:PODD) has observed the following analyst ratings:

Benzinga

Insulet Q1 Earnings Beats Street View, Says Omnipod 5 Rollout Is 'Progressing Very Well'

Insulet Corporation (NASDAQ:PODD) posted Q1 profits of $27.8 million, or an EPS of $0.40, beating the consensus of $0.23. Q1 sales increased 17.1% Y/Y, or 19.3% in constant currency, to $295.4 million, exceeding the guidance range of 13% to 16% in constant currency and the consensus of $288.18 million. “We are off…

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Recap: Insulet Q1 Earnings

Insulet (NASDAQ:PODD) reported its Q1 earnings results on Thursday, May 5, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Insulet beat estimated earnings by 73.91%, reporting an EPS of $0.4 versus an estimate of $0.23.

Benzinga

Insulet Highlights New Data For Omnipod 5 System For Type 1, Type 2 Diabetes

Insulet Corporation (NASDAQ:PODD) unveiled study results for the new Omnipod 5 automated insulin delivery system in type 1 and type 2 diabetes patients. Paired with DexCom Inc's (NASDAQ:DXCM) G6 continuous glucose monitoring (CGM) system, Omnipod 5 is the first tubeless, wearable, automated insulin delivery system. Related: FDA Approves Insulet's Omnipod Automated Insulin Delivery System Patients…

Benzinga

Insulet Posts Street-Beating Q4 Earnings, Omnipod Revenues Up ~20%

Insulet Corp's (NASDAQ: PODD)

Benzinga

Recap: Insulet Q4 Earnings

Insulet (NASDAQ:PODD) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Insulet beat estimated earnings by 31.25%, reporting an EPS of $0.42 versus an estimate of $0.32.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Expert Ratings For Insulet

Analysts have provided the following ratings for Insulet (NASDAQ:PODD) within the last quarter:

Benzinga

FDA Approves Insulet's Omnipod Automated Insulin Delivery System Patients Aged 6 Years & Above

The

Benzinga

Benzinga Pro's Top 5 Stocks To Watch For Friday, Jan. 28, 2022: PODD, KR, TEAM, GOOGL, SBUX

Today's 5 Stock Ideas: Insulet (PODD) - Shares up premarket. The company announced FDA clearance of its Omnipod 5 Automated Insulin Delivery System. Kroger (KR) - Shares down premarket. Citigroup downgraded

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.